Merck's immunotherapy drug succeeds in key bladder cancer trial
October 21, 2016 at 07:04 AM EDT
Oct 21 (Reuters) - Merck & Co Inc said its immunotherapy, Keytruda, helped previously treated patients with advanced bladder cancer live longer in a late-stage study, prompting an independent monitoring panel to recommend stopping the trial early.
